MSF Pharmacist dispensing Bedaquiline and Delamanid based DRTB regimen MSF independent Clinic, Mumbai-India
HIV/Aids

SAMU-Supported Publications 2025

A complete list of publications that the SAMU teams have co-authored, reviewed and supported in 2025.

TB
1GlobalOral Regimens for Rifampin-Resistant,Fluoroquinolone-Susceptible TuberculosisNEJM

2

IndiaSustained treatment success at 12 months for drug-resistant TB patients on concomitant bedaquiline-delamanidIJTLD Open
3South AfricaEnhancing TB case detection among among hospitalized patients through lay health worker led screening: a before-and-after study in KwaZulu-Natal, South AfricaNature
4UkraineEnd of treatment and 12-month post-treatment outcomes in patients treated with all-oral regimens for rifampicin-resistant tuberculosis in Ukraine: a prospective cohort studyPLOS GPH
5PolandHow a refugee crisis revitalised Poland’s tuberculosis careThe Lancet
6IndiaBedaquiline Resistance and Treatment Outcomes Among Patients With Tuberculosis Previously Exposed to Bedaquiline in India: A Multicentric Retrospective Cohort StudyCID
7GlobalCharacteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysisThe Lancet
8GlobalScanned: The global investments in computer-aided detection and ultraportable X-ray for tuberculosisPLOS GPH
9GlobalBedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trialThe Lancet Respiratory Medicine
10GlobalThe Effectiveness of Isoniazid Preventive Treatment among Contacts of Multidrug-Resistant Tuberculosis: A Systematic Review and Individual-Participant Meta-AnalysisAmerican Thoracic Society